SUCCESS RATE OF TALC PLEURODESIS IN PATIENTS WITH MALIGNANT PLEURAL EFFUSION.
DOI:
https://doi.org/10.71000/xxhxn550Keywords:
Hypertension, , Malignant Pleural Effusion, Pleurodesis, Radiographic Monitoring, Talc Slurry, Treatment Outcome, Tumor-Associated EffusionAbstract
Background: Malignant pleural effusion (MPE) is a common complication in advanced malignancies, significantly impairing respiratory function and quality of life. It affects approximately 20% of cancer patients, with lung and breast carcinomas being the leading causes. Pleurodesis using talc is a widely accepted palliative intervention aimed at preventing recurrent fluid accumulation. Despite global data supporting its use, there is a lack of localized evidence evaluating its efficacy in specific population subgroups, warranting further investigation.
Objective: To determine the frequency of success with talc pleurodesis in patients with malignant pleural effusion.
Methods: This descriptive case study was conducted at the Department of Medicine, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, over six months (August 2, 2024 to February 2, 2025). A total of 100 patients aged 18–65 years with radiologically and clinically confirmed MPE were enrolled using non-probability consecutive sampling. Pleurodesis was performed with 5 grams of sterile talc (Steritalc® F2, France) in 90 mL of saline and 10 mL of 1% lidocaine instilled via chest tube. Success was defined as no radiological recurrence of effusion within 30 days post-procedure. Data were analyzed using SPSS version 20.0.
Results: Among 100 patients (mean age 47.5 ± 10.34 years; 69% female), the overall success rate of talc pleurodesis was 71%. A statistically significant association was observed with hypertension, where 81.4% of hypertensive patients experienced success (p = 0.04). No significant associations were found for age (p = 0.29), gender (p > 0.99), BMI (p = 0.66), disease duration (p = 0.97), smoking (p = 0.63), diabetes (p = 0.33), residence (p = 0.32), socioeconomic status (p = 0.97), or procedure time (p = 0.49).
Conclusion: Talc pleurodesis demonstrated considerable efficacy in controlling MPE, with hypertension appearing as a potential predictor of success. These findings support its continued use as a palliative intervention while highlighting the need for further exploration of clinical predictors.
References
Han C, Lee J, Cho JS, Ahn HY. Which is the More Effective Option for Pleurodesis to Prevent the Recurrence of Malignant Pleural Effusion? Large-Particle Talc or Mistletoe Extract (ABNOVA Viscum Injection). J Chest Surg. 2023;56(5):353-8.
Rodrigues A, Souza MEC, Moraes FCA, Lima DP, Carvalho RLC. Talc slurry versus thoracoscopic talc insufflation for malignant pleural effusion: a systematic review and meta-analysis. J Bras Pneumol. 2024;50(3):e20240115.
Wang L, Deng H, Chen X, Li C, Yi F, Wei Y, et al. Talc pleurodesis versus indwelling pleural catheter among patients with malignant pleural effusion: a meta-analysis of randomized controlled trials. World J Surg Oncol. 2020;18(1):184.
Ershadi R, Vahedi M, Zadeh HK, Fathi F, Ebrahimpour H, Zadeh JS, et al. Subcutaneous octreotide therapy for malignant pleural effusion after pleurodesis with talc powder: a placebo-controlled, triple-blind, randomized trial. Support Care Cancer. 2022;30(12):9833-40.
Markowiak T, Ried M, Großer C, Hofmann HS, Hillejan L, Hecker E, et al. Postoperative outcome after palliative treatment of malignant pleural effusion. Thorac Cancer. 2022;13(15):2158-63.
Mohs Z, DeVillers M, Ziegler S, Basson MD, Newman W. Management of Malignant Pleural Effusions in U.S. Veterans: A Retrospective Review. Ann Thorac Cardiovasc Surg. 2022;28(6):420-8.
Muthu V, Dhooria S, Sehgal IS, Prasad KT, Aggarwal AN, Agarwal R. Iodopovidone pleurodesis for malignant pleural effusions: an updated systematic review and meta-analysis. Support Care Cancer. 2021;29(8):4733-42.
Yeung M, Loh EW, Tiong TY, Tam KW. Indwelling pleural catheter versus talc pleurodesis for malignant pleural effusion: a meta-analysis. Clin Exp Metastasis. 2020;37(4):541-9.
Sivakumar P, Fitzgerald DB, Ip H, Rao D, West A, Noorzad F, et al. The impact of outpatient versus inpatient management on health-related quality of life outcomes for patients with malignant pleural effusion: the OPTIMUM randomised clinical trial. Eur Respir J. 2024;63(2).
Lovato JB, Laroumagne S, Tronchetti J, Nguyen NAT, Dutau H, Astoul P. Fast pleurodesis combining talc poudrage and indwelling pleural catheter for the management of recurrent malignant pleural effusions. Respir Med Res. 2024;86:101124.
Mercer RM, Macready J, Jeffries H, Speck N, Kanellakis NI, Maskell NA, et al. Clinically important associations of pleurodesis success in malignant pleural effusion: Analysis of the TIME1 data set. Respirology. 2020;25(7):750-5.
Lau EPM, Ing M, Vekaria S, Tan AL, Charlesworth C, Fysh E, et al. Australasian Malignant PLeural Effusion (AMPLE)-4 trial: study protocol for a multi-centre randomised trial of topical antibiotics prophylaxis for infections of indwelling pleural catheters. Trials. 2024;25(1):249.
Fitzgerald DB, Sidhu C, Budgeon C, Tan AL, Read CA, Kwan BCH, et al. Australasian Malignant PLeural Effusion (AMPLE)-3 trial: study protocol for a multi-centre randomised study comparing indwelling pleural catheter (±talc pleurodesis) versus video-assisted thoracoscopic surgery for management of malignant pleural effusion. Trials. 2022;23(1):530.
Gould Rothberg BE, Quest TE, Yeung SCJ, Pelosof LC, Gerber DE, Seltzer JA, et al. Oncologic emergencies and urgencies: A comprehensive review. CA: Canc J Clin. 2022;72(6):570-93.
Janes SM, Alrifai D, Fennell DA. Perspectives on the treatment of malignant pleural mesothelioma. N Engl J Med. 2021;385(13):1207-18.
Bashour SI, Mankidy BJ, Lazarus DR. Update on the diagnosis and management of malignant pleural effusions. Resp Med. 2022; 196:106802.
Dipper A, Jones HE, Bhatnagar R, Preston NJ, Maskell N, Clive AO. Interventions for the management of malignant pleural effusions: a network meta‐analysis. Cochrane Database Syst Rev. 2020(4): CD010529.
Johnson KE, Popratiloff A, Fan Y, McDonald S, Godleski JJ. Analytic comparison of talc in commercially available baby powder and in pelvic tissues resected from ovarian carcinoma patients. Gynecol Oncol. 2020;159(2):527-33.
Chang Y, Cho D, Cho K, Cho M. Viscum pleurodesis is as effective as talc pleurodesis and tends to have less adverse effect. Support Care Canc. 2020; 28:5463-7.
Hassan M, Harriss E, Mercer RM, Rahman NM. Survival and pleurodesis outcome in patients with malignant pleural effusion–a systematic review. Pleura Peritoneum. 2021;6(1):20200147.
Guerra S, Ferro R, Conceição M, Cunha Â, António C, Torres AS. Outcomes of talc pleurodesis in malignant pleural effusion. Chest. 2020;157(6): A350.
Garcia YA, Palkar A, Koenig SJ, Narasimhan M, Mayo PH. Assessment of diaphragm function and pleural pressures during thoracentesis. Chest. 2020;157(1):205-11.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraj Shehzad, Salma Muhammad Abbas, Muhammad Usman Shabbir (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
